HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

German OTC Launches And Revitalizations From P&G, Stada, Théa and TheOTCLab

Executive Summary

Botanical extracts power new products from P&G Health and Théa Pharmaceuticals in the areas of pain and eye-care respectively, while TheOTCLab and Stada relaunch much-loved foot care and cold brands in this German OTC marketing update. 

You may also be interested in...



People On The Move: Appointments At Cooper, Orkla, TheOTCLab, Dr. Pfleger

A round-up of the latest appointments in Europe's consumer health market: Cooper Consumer Health names Spain & Portugal head; Orkla Health adds to board; TheOTCLab appoints first Germany manager; Dr. Pfleger hires digital specialist.

Prestige Expands UK Eye Care Range In Response To Consumer Demand

A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.

‘Meaningful Revenues’ In 2023 Mark Strategic Milestone As Futura Looks To Future

Futura recorded its first notable revenues last year, generated by the launch of its Eroxon erectile dysfunction gel in the UK and Europe, marking the company's transition from an R&D startup to a consumer healthcare player in its own right. To mark the occasion, CEO James Barder outlines a new strategy, with a focus on innovation in sexual wellness, further global partnerships and sustained profitability. 

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154416

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel